Winckler leaves FDA
This article was originally published in The Tan Sheet
Executive SummarySusan Winckler, FDA chief of staff since January 2007, resigns, giving Commissioner Peggy Hamburg and the Obama administration further room to shape the agency. Winckler joined FDA as director for policy communications in September 2006, after serving as VP of policy and communications and staff counsel for the American Pharmacists Association. An August 2007 reorganization gave FDA's chief of staff a more central role and made deputy commissioners in the Office of the Commissioner report through Winckler (1"The Tan Sheet" Sept. 3, 2007)
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.